Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 4: Results of the multivariable regression model for CLL^{^a}
Estimate (95% CI) P Value
RR 
    Count model coefficients 
        Female sex 3.99 (1.53–10.41) .005
        Age at cranial RT ^{^b} 0.51 (0.27–0.97) .041
OR 
    Zero hurdle model coefficients 
        Age at cranial RT ^{^b} 0.51 (0.30–0.88) .015
        Treatment protocol (CT-RT) 3.20 (1.17–8.75) .024
Note:—RR indicates rate ratio; CT, chemotherapy.
↵a Reference categories are male sex, no chemoradiotherapy. P values were obtained by the hurdle regression model.
↵b For each 4-year increase.

Estimate (95% CI)		P Value
RR
Count model coefficients
Female sex	3.99 (1.53–10.41)	.005
Age at cranial RT ^{^b}	0.51 (0.27–0.97)	.041
OR
Zero hurdle model coefficients
Age at cranial RT ^{^b}	0.51 (0.30–0.88)	.015
Treatment protocol (CT-RT)	3.20 (1.17–8.75)	.024